Novartis Investigative Site

Trieste, TS 34149

2 studies enrolling now · 12 studies all time

What they study most

Acute Heart Failure, Acute Myocardial Infarction, Chronic Heart Failure, Healthy Volunteers, Pulmonary Arterial Hypertension, Heart Failure, Heart Failure With Preserved Ejection Fraction, Hereditary Periodic Fevers, Immune Thrombocytopenic Purpura (ITP), PIK3CA-related Overgrowth Spectrum (PROS), Parkinson's Disease Dementia, Primary Immune Thrombocytopenia, Primary Immune Thrombocytopenia (ITP)

Studies at this site

• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) — Recruiting now
• EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) — Recruiting now
• A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids — Running, not enrolling
• Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) — Running, not enrolling
• A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure — Stopped early
• A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP — Completed
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers — Completed
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed
• Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD) — Completed